OTLK Stock Overview
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Outlook Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.19 |
| 52 Week High | US$40.60 |
| 52 Week Low | US$4.00 |
| Beta | 0.19 |
| 1 Month Change | -5.65% |
| 3 Month Change | -5.21% |
| 1 Year Change | -61.37% |
| 3 Year Change | -82.42% |
| 5 Year Change | -67.50% |
| Change since IPO | -98.80% |
Recent News & Updates
Recent updates
Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?
Nov 03
Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%
Aug 30Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01
Aug 10Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?
Jul 06Outlook Therapeutics announces full cash pre-payment of convertible promissory note
Jul 05Outlook Therapeutics: A One-Buck Lottery Ticket
Jun 09Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?
Apr 01Outlook Therapeutics: Likely FDA Approval, Possible Buyout
Jan 21Outlook Therapeutics (NASDAQ:OTLK) Has Debt But No Earnings; Should You Worry?
Jun 24Outlook Therapeutics completes patient dosing in wet AMD trial
Jun 08Shareholder Returns
| OTLK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.2% | 0.4% | 1.0% |
| 1Y | -61.4% | 0.9% | 21.9% |
Return vs Industry: OTLK underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: OTLK underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| OTLK volatility | |
|---|---|
| OTLK Average Weekly Movement | 20.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OTLK's share price has been volatile over the past 3 months.
Volatility Over Time: OTLK's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 24 | Russ Trenary | www.outlooktherapeutics.com |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte.
Outlook Therapeutics, Inc. Fundamentals Summary
| OTLK fundamental statistics | |
|---|---|
| Market cap | US$182.63m |
| Earnings (TTM) | -US$51.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs OTLK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTLK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$21.12m |
| Gross Profit | -US$21.12m |
| Other Expenses | US$30.38m |
| Earnings | -US$51.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -150.1% |
How did OTLK perform over the long term?
See historical performance and comparison